Prosper Subgroup Analysis By Age And Region: Overall Survival And Safety In Men With Nonmetastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy Plus Enzalutamide.

Ugo De Giorgi,Maha H. A. Hussain,Neal D. Shore,Karim Fizazi,Bertrand Tombal,David F. Penson,Fred Saad,Eleni Efstathiou,Katarzyna Madziarska,Joyce Leta Steinberg,Jennifer Sugg,Xun Lin,Qi Shen,Cora N. Sternberg

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览13

暂无评分

摘要

84Background: Previous reports on the PROSPER trial have shown that enzalutamide (ENZA) plus androgen deprivation therapy (ADT) significantly improves metastasis-free survival and overall survival ...

查看译文

关键词

Androgen deprivation therapy,Enzalutamide,Prostate cancer,Subgroup analysis,Oncology,Medicine,Castration resistant,Internal medicine,Overall survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要